Clinical Trial Update: Anti-infection of Low-does IL-2 in SLE [NA]

View source ↗

Summary

A completed clinical trial at Peking University People's Hospital evaluating low-dose interleukin-2 for systemic lupus erythematosus.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Systemic Lupus Erythematosus

Drugs mentioned

• Low-dose Interleukin-2 (interleukin-2)

Snippet

Sponsor: Peking University People's Hospital | Conditions: Systemic Lupus Erythematosus | NA | Status: COMPLETED